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Intra-abdominal fat is associated with insulin
resistance and cardiovascular risk. Levels of
serum retinol-binding protein (RBP4), secreted
by fat and liver cells, are increased in obesity
and type 2 diabetes (T2D). Here we report
that, in 196 subjects, RBP4 is preferentially
expressed in visceral (Vis) versus subcutaneous
(SC) fat. Vis fatRBP4mRNAwas increased60-
fold and 12-fold in Vis and SC obese subjects
respectively versus lean subjects, and 2-fold
with impaired glucose tolerance/T2D subjects
versus normoglycemic subjects. In obese
subjects, serum RBP4 was increased 2- to 3-
fold, and serum transthyretin, which stabilizes
RBP4 in the circulation, was increased 35%.
Serum RBP4 correlated positively with adipose
RBP4mRNA and intra-abdominal fat mass and
inversely with insulin sensitivity, independently
of age, gender, and body mass index. RBP4
mRNA correlated inversely with GLUT4 mRNA
in Vis fat and positively with adipocyte size in
both depots. RBP4 levels are therefore linked
to Vis adiposity, and Vis fat may be a major
source of RBP4 in insulin-resistant states.
INTRODUCTION
Increased intra-abdominal (i.e., visceral) adipose tissue is
associated with insulin resistance, type 2 diabetes (T2D),
and cardiovascular disease (Bjorntorp, 1991; Frayn,
2000; Wajchenberg, 2000). Reducing visceral adipose
mass by omentectomy improves glucose metabolism
and insulin sensitivity and reduces cardiovascular risk
factors in obese subjects (Thorne et al., 2002), whereas
decreasing subcutaneous adipose tissue mass does not(Klein et al., 2004). Many adipocyte-secreted proteins
that influence insulin action or development of cardio-
vascular disease also exhibit adipose-depot-specific
expression (Shimomura et al., 1996; Alessi et al., 1997;
Van Harmelen et al., 1998; Fried et al., 1998; Statnick
et al., 2000; Fisher et al., 2002; Fukuhara et al., 2005).
Therefore, enhanced expression of adipocyte-secreted
proteins in visceral fat could contribute to the pathogene-
sis of insulin resistance, T2D, and cardiovascular disease.
Downregulation of glucose transporter 4 (GLUT4) in
adipocytes is a common feature of many insulin-resistant
states, including obesity and T2D (Shepherd and Kahn,
1999). Mice with adipose-specific knockout of Glut4
(adipose-Glut4 KO mice) develop systemic insulin resis-
tance with impaired insulin action in muscle, liver, and
adipose tissue (Abel et al., 2001). Serum retinol-binding
protein (Rbp4) expression in adipose tissue and serum
RBP4 concentrations are increased in these mice, and
serum RBP4 levels are increased in multiple other models
of insulin resistance (Yang et al., 2005). RBP4 is a 21 kDa
secreted protein that is the sole specific transport protein
for vitamin A (retinol) in blood (Blaner, 1989). Studies in
mice suggest that elevated serum RBP4 could play
a causal role in insulin resistance. Increasing serum
RBP4 concentrations by transgenic overexpression or
by injection of purified RBP4 protein into wild-type mice
causes insulin resistance (Yang et al., 2005). Conversely,
Rbp4 knockout mice (both homozygous and heterozy-
gous) exhibit enhanced insulin sensitivity, and treatment
with fenretinide, a synthetic retinoid, lowers serum RBP4
and improves insulin sensitivity and glucose tolerance in
mice on a high-fat diet (Yang et al., 2005).
Serum RBP4 concentrations are also elevated in
insulin-resistant humans with obesity, T2D, or impaired
glucose tolerance (IGT), and even in lean normoglycemic
subjects with a strong family history of T2D (Yang et al.,
2005; Graham et al., 2006). A number of studies in humans
show that serum RBP4 levels correlate inversely with
insulin sensitivity and/or HDL cholesterol levels and/or
positively with many other components of the metabolicCell Metabolism 6, 79–87, July 2007 ª2007 Elsevier Inc. 79
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triglycerides, and systolic blood pressure (Graham et al.,
2006; Yoshida et al., 2006; Cho et al., 2006; Stefan
et al., 2007; Haider et al., 2007a, 2007b; Gavi et al.,
2007; Lee et al., 2007; Balagopal et al., 2007). Improving
insulin sensitivity by interventions such as exercise
training, ‘‘lifestyle modification,’’ or gastric banding sur-
gery is associated with lowering of serumRBP4 in humans
(Graham et al., 2006; Balagopal et al., 2007; Haider et al.,
2007a). In addition, treatment with the insulin-sensitizing
drug rosiglitazone lowers serum RBP4 levels in subjects
with HIV (Haider et al., 2007b). Hence, serum RBP4 levels
may aid in identifying subjects at higher risk for diabetes
and cardiovascular disease and may provide a useful
index for responses to some therapeutic interventions.
Two studies have found a genetic association between
single nucleotide polymorphisms (SNPs) in theRBP4 gene
and insulin resistance, impaired insulin secretion, and/or
T2D (Munkhtulga et al., 2007; Craig et al., 2007). One
gain-of-function SNP that is associated with increased
risk for T2D is located in the RBP4 promoter region and
enhances RBP4 gene transcription, resulting in increased
serum concentrations of RBP4 in diabetic subjects
(Munkhtulga et al., 2007). Two other studies have reported
no association between serum RBP4 levels andmeasures
of insulin resistance or components of the metabolic syn-
drome (Janke et al., 2006; Silha et al., 2007), and one of
these studies did not find elevatedRBP4mRNA in adipose
tissue of insulin-resistant subjects (Janke et al., 2006).
Disagreements in findings may reflect differences in
underlying characteristics of the study groups, inappropri-
ate use of homeostatic model assessment of insulin resis-
tance (HOMA-IR) in diabetic subjects, or problems with
the commercially available kits for measuring serum
RBP4 (Graham et al., 2007).
Since serum RBP4 concentrations in humans correlate
highly with waist-to-hip circumference ratio (an anthropo-
metric estimate of intra-abdominal adipose mass)
(Graham et al., 2006), waist circumference (Cho et al.,
2006), and percent trunk fat (Gavi et al., 2007), visceral
adiposity could be a determinant of serum RBP4 concen-
trations. RBP4 production in visceral adipose tissue could
therefore be one mechanism by which visceral adiposity
promotes the development of insulin resistance and the
metabolic syndrome. However, it is unknown whether
RBP4 expression is adipose depot-specific or whether
the quantity of visceral adipose tissue could be a determi-
nant of elevated serum RBP4 levels in insulin-resistant
humans. The relationship of RBP4 expression to adipo-
cyte size is also unknown.
RESULTS
Higher RBP4 mRNA Levels in Visceral
Adipose Tissue
Analysis of paired visceral (Vis) and subcutaneous (SC)
adipose tissue biopsy specimens from 196 lean and
obese subjects revealed that RBP4 mRNA was 5-fold
higher in Vis than in SC adipose tissue (Figure 1A) in80 Cell Metabolism 6, 79–87, July 2007 ª2007 Elsevier Inc.both men and women (Figure 1B). Subjects with T2D or
IGT exhibited 2-fold increased expression of RBP4
mRNA in Vis adipose tissue versus subjects with normal
glucose tolerance (NGT, Figure 1C), consistent with find-
ings suggested by differential display analysis of Vis
adipose tissue mRNA from 8 obese subjects (Corominola
et al., 2001). Among the 196 individual subjects studied,
RBP4 mRNA was greater in Vis than in SC adipose tissue
of 176 subjects, greater in SC than in Vis adipose tissue of
18 subjects, and expressed equally in the depots of 2
subjects.
Since increased intra-abdominal fat mass is associated
with changes in adipose biology, including adipocyte
enlargement and altered adipocyte-secreted protein
expression (Wajchenberg, 2000; Ravussin and Smith,
2002), we sought to determine whether intra-abdominal
adipose mass or the relative proportion of Vis adipose
tissue correlates with RBP4mRNA expression and serum
RBP4 concentrations. Lean and obese subjects were
categorized as having a predominance of Vis or SC
adiposity on the basis of intra-abdominal and SC fat areas
measured by quantitative CT scanning (Table 1). Obese
subjects with Vis adiposity exhibited a greater degree of
insulin resistance (glucose infusion rate during clamp),
higher serum concentrations of free fatty acids, and lower
adiponectin concentrations than obese subjects with SC
adiposity, whereas BMI, fasting glucose, fasting insulin,
and HbA1c did not differ between the two obese groups
(Table 1).
RBP4mRNA was increased in both Vis and SC adipose
tissue of obese versus lean subjects (Figure 1D). However,
Vis obesity was associated with greater RBP4 expression
in both Vis and SC adipose depots, and more markedly in
the Vis adipose depot, where it was6-fold higher than in
subjects with SC obesity. For individual subjects, RBP4
expression in Vis versus SC adipose depots was corre-
lated (r = 0.45, p < 0.01; data not shown). Serum RBP4
concentrations correlated strongly with RBP4 mRNA
expression in Vis adipose tissue (Figure 1E) and also,
albeit less strongly, in SC adipose tissue (Figure 1F).
RBP4 mRNA correlated negatively with GLUT4 mRNA in
Vis fat (Figure 1G), but not in SC fat (Figure 1H). RBP4
mRNA correlated strongly with adipocyte size (volume)
in both Vis and SC adipocytes (Figure 1I). However,
when matched for adipocyte size, RBP4 mRNA was
greater in Vis than in SC adipocytes of most subjects
(Figure 1I). Serum RBP4 levels also correlated strongly
with adipocyte size in both Vis (r = 0.63, p < 0.001)
and SC (r = 0.59, p < 0.001) adipose tissue (data not
shown).
Serum RBP4, Intra-abdominal Adipose Tissue,
and Insulin Sensitivity
Among both lean and obese subjects, those with T2D or
IGT had higher RBP4 serum concentrations than subjects
with NGT (Figure 2A). Not all NGT subjects were lean. The
mean RBP4 concentration for lean NGT subjects was
34 ± 7 mg/ml, which was 45% lower than in obese NGT
subjects (62 ± 10 mg/ml). Obese NGT subjects with Vis
Cell Metabolism
RBP4 in Visceral and Subcutaneous Adipose TissueFigure 1. Relationship between RBP4mRNA in Adipose Tissue Depots and Serum RBP4 Concentrations, Adipose Tissue GLUT4
mRNA, and Adipocyte Size in Human Subjects
(A–D)RBP4mRNA levels in entire study population (n = 196), including lean, obese, nondiabetic, and diabetic subjects (A), males (n = 98) and females
(n = 98) (B), normal glucose tolerance (NGT) subjects (n = 129) or impaired glucose tolerance (IGT) and type 2 diabetes (T2D) subjects grouped
together (n = 67) (C), and subgroups of lean (n = 53), visceral obese (Vis, n = 21), and subcutaneous obese (SC, n = 55) subjects with NGT (D).
(E and F) Correlations between serum RBP4 concentration and RBP4 mRNA expression in Vis adipose tissue (n = 163) (E) and SC adipose tissue
(n = 163) (F).
(G and H) Correlation between RBP4 mRNA and GLUT4 mRNA in Vis adipose tissue (n = 196) (G) and SC adipose tissue (n = 196) (H).
(I) Correlation between adipocyte size and RBP4 mRNA in Vis (d) and SC (B) adipose tissue biopsies from lean, SC obese, and Vis obese subjects
(n = 20 per group of mixed NGT, IGT, and T2D subjects).
Data were log transformed to achieve a normal distribution. (E) and (F) include those subjects for whom measurements of all parameters were avail-
able (i.e., serum RBP4 was measured in 163 of the 196 subjects). Vis fat area and the relative ratio of Vis fat to SC fat area were calculated using CT
scans at the level of L4–L5. Values are means ± SEM. *p < 0.01; **p < 0.001 for bracketed comparisons. #p < 0.01 for NGT versus IGT/T2D groups for
the same fat depot in (C); ap < 0.01 for obese groups versus the lean group comparing the same fat depot in (D); bp < 0.01 for the Vis obese group
versus SC obese group comparing the same fat depot in (D).adiposity had the highest serum RBP4 concentrations
(3-fold greater than lean NGT subjects and 30%
greater than obese NGT subjects with SC adiposity;
Figure 2B). Relative to lean subjects, NGT subjects with
SC obesity exhibited 2-fold elevated serum RBP4
(Figure 2B). Serum RBP4 concentrations did not differ be-
tween men and women within the different groups (data
not shown). As previously reported (Graham et al.,
2006), serum RBP4 concentrations correlated inversely
with glucose disposal rate (GDR) during clamp studies
(r = 0.50, p < 0.001; see Figure S1A in the SupplementalData available with this article online) even after multivar-
iate linear regression analysis adjusting for age, gender,
and % body fat (data not shown). Setting an upper limit
for the glucose infusion rate resulted in a lower correlation
constant (r) than would have been obtained without this
arbitrary upper limit.
Serum RBP4 correlated directly with BMI (r = 0.63, p <
0.001), waist circumference (r = 0.58, p < 0.001), fasting
plasma glucose concentrations (r = 0.47, p < 0.01), LDL
cholesterol concentrations (r = 0.45, p < 0.01), and triglyc-
eride concentrations (r = 0.42, p < 0.01) and inversely withCell Metabolism 6, 79–87, July 2007 ª2007 Elsevier Inc. 81
Table 1. Anthropometric and Metabolic Characteristics of Subjects by Subgroups
e or Type 2 Diabetes
Visceral
Obese
Subcutaneous
Obese
n = 21 33
Age ( 3.2a 61.4 ± 3.7 53.6 ± 3.2
BMI ( 0.2 34.0 ± 1.55b 34.4 ± 1.8b
WHR 0.02 1.1 ± 0.03b 1.1 ± 0.05b
Body 0.5 33.4 ± 2.0b 39.5 ± 2.9b,c
Visce 2.1a 296.4 ± 16.9b 173.4 ± 14.1b,c
SC fa 2.9 428 ± 57.0b 936.3 ± 61.1b,c
HbA1 0.05a 6.2 ± 0.1a 6.1 ± 0.1a
Fastin 0.2a 6.2 ± 0.20a,b 6.4 ± 0.2a,b
Fastin 115a 262.3 ± 23.9a 282.0 ± 46.4a
2 hr O 2.7a 12.0 ± 1.1a 11.6 ± 1.0a
Clam 6.9a 26.3 ± 4.9a 49.3 ± 9.9a,b,c
FFA ( 0.01a 0.8 ± 0.08b 0.6 ± 0.1
Total 0.13a 6.0 ± 0.2a,b 5.5 ± 0.2
HDL c 0.05a 1.3 ± 0.1b 1.4 ± 0.08b
LDL c 0.5 3.6 ± 0.2b 3.5 ± 0.2a
Trigly 0.3a 2.5 ± 0.4a,b 2.6 ± 0.3a,b
Leptin
Ma 0.3 20.4 ± 4.6b 14.3 ± 2.4a,b,c
Fem 0.5 38.6 ± 6.0b 32.3 ± 3.2b
IL-6 ( 0.8 6.2 ± 3.1b 5.3 ± 2.7a,b,c
Visfat 1.9 281.7 ± 24.1a,b 180.2 ± 22.1a,b,c
Adipo 3.7 2.3 ± 1.8a,b 5.3 ± 2.5b,c
Blood
a p < eral [Vis] obese, or subcutaneous [SC] obese).
b p <
c p <
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eNormal Glucose Tolerance Impaired Glucose Toleranc
All Lean
Visceral
Obese
Subcutaneous
Obese All Lean
129 53 21 55 67 13
years) 54 ± 15 48.8 ± 2.4 61.2 ± 2.6 57.8 ± 2.2 57 ± 13 39.0 ±
kg/cm2) 29.3 ± 6.8 24.0 ± 0.15 32.3 ± 1.27b 34.7 ± 0.9b 35.0 ± 6.3a 24.6 ±
(waist/hip ratio) 0.97 ± 0.17 0.85 ± 0.02 1.12 ± 0.02b 1.0 ± 0.02b 1.09 ± 0.12a 0.88 ±
fat (%) 30.0 ± 10.1 21.6 ± 0.36 31.8 ± 1.15b 38.7 ± 1.4b,c 38.1 ± 9.3a 27 ±
ral fat area (cm2) 171.8 ± 19.2 48.4 ± 2.4 292.7 ± 12.3b 161.2 ± 9.1b,c 180.1 ± 19.4a 76.5 ±
t area (cm2) 429.1 ± 33.2 55.8 ± 2.8 404 ± 28.7b 801.2 ± 91b,c 468.4 ± 52.7 56 ±
c 5.4 ± 0.2 5.3 ± 0.03 5.66 ± 0.06b 5.5 ± 0.04 6.3 ± 0.7a 6.3 ±
g blood glucose (mmol/l) 5.3 ± 0.4 5.3 ± 0.05 5.3 ± 0.10 5.3 ± 0.08 6.6 ± 1.4a 7.8 ±
g plasma insulin (pmol/l) 79 ± 68 12.5 ± 2.4 125.3 ± 16.8b 112.0 ± 9.0b 279 ± 120a 241.1 ±
GTT blood glucose (mmol/l) 6.1 ± 0.7 5.9 ± 0.1 6.3 ± 0.20 6.0 ± 0.1 11.3 ± 1.8a 10.7 ±
p glucose infusion rate (ml/hr) 76 ± 26 96.0 ± 1.23 48.0 ± 6.6b 65.2 ± 4.1b,c 34 ± 20a 28.5 ±
mmol/l) 0.46 ± 0.3 0.3 ± 0.02 0.7 ± 0.06b 0.5 ± 0.04b,c 0.71 ± 0.035a 0.6 ±
cholesterol (mmol/l) 4.9 ± 0.7 4.3 ± 0.11 5.6 ± 0.2b 5.0 ± 0.1b,c 5.7 ± 0.7a 5.3 ±
holesterol (mmol/l) 1.5 ± 0.09 1.6 ± 0.08 1.3 ± 0.05b 1.4 ± 0.05b,c 1.3 ± 0.11a 1.0 ±
holesterol (mmol/l) 2.7 ± 0.7 2.9 ± 0.11 3.3 ± 0.1b 2.6 ± 0.08b 3.5 ± 0.7a 3.2 ±
cerides 1.5 ± 0.3 0.9 ± 0.2 2.1 ± 0.3b 1.6 ± 0.4b,c 2.3 ± 0.4a 2.1 ±
les 12.7 ± 11 3.3 ± 0.80 22.9 ± 2.9b 21.5 ± 1.9b 19.9 ± 13.5a 3.8 ±
ales 21.8 ± 14.3 8.4 ± 1.0 32.3 ± 3.7b 28.0 ± 2.2b 34.9 ± 11.2a 9.2 ±
pmol/l) 2.4 ± 2.5 0.92 ± 0.12 4.4 ± 2.2b 1.9 ± 1.1b,c 4.2 ± 3.0a 1.1 ±
in (ng/ml) 87 ± 9.5 16.0 ± 1.9 156 ± 17.4 89.3 ± 16.3 160 ± 19.4 19.3 ±
nectin (ng/ml) 7.7 ± 4.5 11.2 ± 4.7 4.8 ± 2.7b 6.9 ± 3.6b,c 5.6 ± 3.3a 9.2 ±
was drawn after an overnight fast. Data are means ± SEM.
0.05 for impaired glucose tolerance/type 2 diabetes versus normal glucose tolerance within the same subgroup (i.e., all, lean, visc
0.05 between Vis obese or SC obese and lean.
0.05 between Vis obese and SC obese.
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RBP4 in Visceral and Subcutaneous Adipose TissueFigure 2. Serum RBP4 and Transthyretin
Concentrations in Lean, Obese, and
IGT/T2D Subjects
(A) Serum RBP4 concentrations in healthy lean
and obese subjects with NGT (n = 129) and
subjects with IGT/T2D (n = 67). Horizontal lines
in all panels represent means of the values.
(B) Serum RBP4 concentrations in NGT sub-
groups: lean NGT (n = 53), Vis obese NGT
(n = 21), and SC obese NGT (n = 55). In (B),
(E), (F), and (H), to categorize obese subjects
according to patterns of adipose tissue distri-
bution, intra-abdominal (Vis) fat area (IAFA)
and SC fat area were measured using CT
scans at the level of L4–L5, and the relative ra-
tio of Vis to SC fat area was calculated.
(C and D) Relationship between serum RBP4
concentrations and % total body fat (C) or
IAFA (D) in lean, obese, NGT, IGT, and T2D
subjects (n = 163). In (C)–(F), data were log
transformed to achieve a normal distribution.
Data in (C)–(H) include only those subjects for
whom all parameters were available.
(E and F) Correlation between serum RBP4
concentration and fasting plasma insulin in
Vis obese subjects (n = 29) (E) and SC obese
subjects (n = 73) (F).
(G) Serum transthyretin (TTR) concentrations in
healthy lean and obese NGT subjects (n = 129)
and subjects with IGT/T2D (n = 51).
(H) Serum TTR concentrations in subgroups of
lean (n = 53), Vis obese (n = 21), and SC obese
(n = 55) subjects with NGT.
*p < 0.05; **p < 0.01; ***p < 0.001 for bracketed
comparisons.HDL cholesterol concentrations (r = 0.33, p < 0.01).
Furthermore, serum RBP4 concentrations correlated
with HbA1c (Figure S1B), % body fat (Figure 2C), and
intra-abdominal fat area (Figure 2D). The magnitude of
the bivariate correlation between serum RBP4 and intra-
abdominal fat area (r = 0.52, p < 0.001; Figure 2D) was
greater than that observed for several other adipocyte-
secreted proteins implicated in insulin resistance: adipo-
nectin, r = 0.30, p = 0.08; leptin, r = 0.39, p < 0.01;
IL-6, r = 0.14, p = 0.58; and visfatin, r < 0.01, p = 0.70,
even in gender-specific analyses (Table S1).
SerumRBP4 correlatedmore highly with fasting plasma
insulin in NGT subjects with Vis obesity (Figure 2E) than in
NGT subjects with SC obesity (Figure 2F). Correlations of
serumRBP4with HbA1c,%body fat, and intra-abdominal
fat area remained significant after adjusting for age, BMI,
and gender by multivariate analysis. The correlation be-tween serum RBP4 and intra-abdominal fat area also re-
mained significant after adjusting for % body fat.
Serum Transthyretin and the RBP4/TTR Ratio
In serum, RBP4 is bound almost entirely to transthyretin
(TTR), or ‘‘prealbumin,’’ in a 1:1 molar complex (Monaco,
2000). Binding of RBP4 to the 56 kDa TTR tetramer stabi-
lizes RBP4 in the circulation by preventing its glomerular
filtration (Monaco, 2000; Zanotti and Berni, 2004). How-
ever, TTR is present in serum at a molar excess over
RBP4 (Zanotti and Berni, 2004) under normal conditions.
Serum TTR concentrations did not differ between men
and women. TTR was 20% greater in IGT and T2D sub-
jects versus NGT subjects (Figure 2G) and 35% greater
in NGT subjects with either Vis or SC obesity versus lean
subjects (Figure 2H). TTR concentrations were higher in
subjects with Vis versus SC obesity (Figure 2H). DespiteCell Metabolism 6, 79–87, July 2007 ª2007 Elsevier Inc. 83
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RBP4 in Visceral and Subcutaneous Adipose TissueTable 2. Multivariate Regression Analysis of Adipocyte-Secreted Proteins as Predictors of Glucose Infusion Rate
during Clamp or of Intra-abdominal Fat Area
Glucose Infusion Rate during Steady State of Clamp Intra-abdominal Fat Area
All b
Coefficient
Male b
Coefficient
Female b
Coefficient
All b
Coefficient
Male b
Coefficient
Female b
Coefficient
RBP4 0.71 (<0.0001) 0.82 (<0.0001) 0.61 (<0.0001) 0.42 (<0.01) 0.49 (0.001) 0.35 (0.001)
Leptin 0.27 (<0.001) 0.043 (0.63) 0.47 (<0.0001) 0.31 (0.02) 0.28 (0.03) 0.32 (0.02)
Adiponectin 0.062 (0.37) 0.13 (0.10) 0.06 (0.51) 0.19 (0.18) 0.21 (0.05) 0.17 (0.08)
IL-6 0.039 (0.58) 0.012 (0.20) 0.07 (0.1) 0.15 (0.43) 0.15 (0.09) 0.01 (0.8)
Visfatin 0.018 (0.75) 0.058 (0.60) 0.10 (0.1) 0.09 (0.67) 0.02 (0.5) 0.08 (0.7)
Blood was drawn after an overnight fast. Analysis for glucose infusion rate includes 163 lean and obese subjects (96 with normal
glucose tolerance, 67with impaired glucose tolerance or type 2 diabetes) for whommeasurements of all parameterswere available.
Analysis for intra-abdominal fat area includes 130 obese subjects. Intra-abdominal fat area was calculated in all Vis obese subjects
(n = 42) and all SC obese subjects (n = 88). Lean subjects are not included in the analysis of predictors of intra-abdominal fat area.
p values are listed in parentheses.elevation of both RBP4 and TTR in obese subjects, the rel-
ative molar ratio of RBP4 to TTR was higher in obese ver-
sus lean subjects and in obese NGT subjects with Vis ad-
iposity versus SC adiposity (data not shown), indicating
that a greater molar fraction of TTR may be bound to
RBP4. Thus, differences in RBP4:TTR affinity may also
contribute to the elevated RBP4 levels in obese subjects.
Predictive Values of Adipocyte-Secreted Proteins
Multivariate linear regression analysis of age, % body fat,
Vis and SC fat RBP4 mRNA expression, HbA1c, and
glucose infusion rate during the clamp as predictors for
serum RBP4 concentrations revealed that Vis fat RBP4
expression is the single strongest determinant of circulat-
ing serum RBP4 (data not shown). In addition, HbA1c and
glucose infusion rate during the clamp exhibited signifi-
cant independent relationships with serum RBP4 (data
not shown).
To evaluate the predictive value of serumRBP4 for insu-
lin resistance and intra-abdominal fat mass compared to
other adipocyte-secreted proteins, we performed an addi-
tional multivariate linear regression analysis using glucose
infusion rate during the clamp or intra-abdominal fat
area as dependent variables. Among adipocyte-secreted
proteins, including adiponectin, IL-6, visfatin, and leptin,
RBP4 was the best predictor of insulin resistance and the
best overall marker for intra-abdominal fat mass by multi-
variate (Table 2) or bivariate analysis (Table S1). These
results were seen in the whole group and also with gen-
der-specific analysis, except that in women, serum leptin
concentrations were comparable to RBP4 in predicting
intra-abdominal fat mass in multivariate analysis (Table 2).
DISCUSSION
This study provides new mechanistic insight into the rela-
tionship between adiposity and RBP4 expression in hu-
man subjects. RBP4 expression is higher in Vis versus
SC adipose tissue, regardless of gender, percent body
fat, fat distribution, the presence or absence of IGT/T2D,
or adipocyte size. RBP4 mRNA correlates highly with ad-84 Cell Metabolism 6, 79–87, July 2007 ª2007 Elsevier Inc.ipocyte size in both Vis and SC adipose tissue, but when
adipocytes are matched for size, RBP4 mRNA is greater
in Vis adipose tissue. Therefore, additional factors appear
to increase RBP4 expression in Vis adipose tissue. We
find a negative correlation between RBP4 mRNA and
GLUT4 mRNA in Vis, but not SC, adipose tissue. Thus,
the decreased GLUT4 expression and insulin-stimulated
glucose transport in adipose tissue commonly seen in
insulin-resistant obese and diabetic states (Shepherd
and Kahn, 1999) may elicit a ‘‘signal’’ in Vis fat that induces
RBP4 expression. Serum RBP4 concentrations correlate
with RBP4 mRNA in both Vis and SC fat, although more
highly in Vis fat. Compared to other adipocyte-secreted
proteins, serum RBP4 levels are the strongest marker for
insulin resistance and accumulation of intra-abdominal
adipose tissue.
While hepatocytes are regarded as the major source of
RBP4 under normal conditions, adipose tissue expresses
a considerable amount of RBP4 (Tsutsumi et al., 1992) and
could contribute to elevated serum concentrations in
insulin-resistant states, especially when adipose mass is
increased. Because SC fat mass is greater than Vis fat
mass (Abate et al., 1996), it is likely that SC fat makes
a substantial contribution to serum RBP4 levels. In-
creased production of RBP4 in Vis fat might contribute
more directly to the development of insulin resistance in
liver by increasing RBP4 levels in the portal circulation.
Hepatocyte RBP4 production may also be increased in
our subjects. However, Rbp4 mRNA is increased in adi-
pose tissue and not in liver of insulin-resistant adipose-
specific Glut4 knockout mice (Yang et al., 2005).
Increasing evidence suggests that insulin resistance is
associated with inflammatory changes in adipose tissue
that may include macrophage infiltration. We did not find
significant quantities of RBP4 mRNA in the stromovascu-
lar component where macrophages fractionate, in either
mouse adipose tissue or human Vis or SC adipose tissue,
even in insulin-resistant states (data not shown). Thus, in-
filtrating macrophages are unlikely to contribute to RBP4
mRNA in adipose tissue or to circulating RBP4 levels in
insulin-resistant humans.
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RBP4 in Visceral and Subcutaneous Adipose TissueThe strong association in this study and others (Gra-
ham et al., 2006; Yoshida et al., 2006; Cho et al., 2006;
Stefan et al., 2007; Haider et al., 2007a; Gavi et al.,
2007; Lee et al., 2007; Balagopal et al., 2007) between
elevated serum RBP4 concentrations and components
of the metabolic syndrome, including increased BMI
and waist circumference, contrasts with recent reports
in which serum RBP4 was not increased in overweight
or obese women (Janke et al., 2006) or in a group of
aboriginal Canadian women (Silha et al., 2007). Different
methods for measuring RBP4 concentrations may con-
tribute to these different results since many available as-
says have methodological problems (Graham et al.,
2007). We also did not find the positive correlation be-
tween RBP4 and GLUT4 expression in SC adipose tissue
reported by Janke et al. (2006). Potentially, this results
from differences in the method of normalization of
RBP4 and GLUT4 mRNA since GAPDH expression as
used by Janke et al. (2006) varies with different metabolic
conditions, including obesity (Alexander et al., 1988;
Dugail et al., 1992). We replicated our RBP4 mRNA re-
sults, including the negative correlation between RBP4
and GLUT4 mRNAs in Vis adipose tissue, with two differ-
ent sets of RBP4 primers, including those used by Janke
et al. (2006). Stefan et al. (2007) found correlations of
serum RBP4 and insulin resistance with intrahepatic lipid
content but not visceral adipose mass measured by MRI
tomography. Since Stefan et al. (2007) did not find
a strong correlation between insulin resistance and either
total or visceral adiposity, it is difficult to compare their
subjects to ours.
Our finding that serum RBP4 is the strongest predictor
of both insulin resistance and intra-abdominal adipose tis-
sue mass among different adipocyte-secreted proteins
supports the possibility that RBP4 may play an important
role in pathogenesis of the metabolic syndrome. Although
these findings alone are not sufficient to establish a causal
role for elevated serum RBP4 in insulin resistance in hu-
mans, previous studies inmice have demonstrated that el-
evation of serum RBP4 can cause or worsen insulin resis-
tance (Yang et al., 2005). The degree to which RBP4
contributes to the pathogenesis of insulin resistance in hu-
mans is not known, and factors other than RBP4 (e.g., free
fatty acids) that differ in relation to Vis versus SC adiposity
are likely to also contribute to the increasedmetabolic and
cardiovascular morbidity associated with Vis adiposity.
SerumTTR, the binding partner of RBP4 in circulation, is
elevated in obese and IGT/T2D subjects, and its levels are
higher in Vis versus SC obesity. Since TTR stabilizes RBP4
in circulation by preventing its renal excretion, increased
RBP4:TTR binding could contribute to RBP4 elevation in
obese and IGT/T2D subjects. RBP4:TTR binding may
also influence biological actions of TTR, including its
effects on lipid metabolism and insulin secretion (Scantle-
bury et al., 1998; Refai et al., 2005).
In conclusion, among several adipocyte-secreted
proteins considered to be important in regulating insulin-
glucose homeostasis, serum RBP4 concentrations
appear to be the best indicator of insulin resistance andintra-abdominal adipose mass. This suggests a potential
role for RBP4 as a convenient marker not only for T2D
but also for cardiovascular risk. In addition, RBP4 may
provide a mechanistic link between Vis adipose tissue
accumulation and the increased metabolic and cardio-
vascular risks associated with it.
EXPERIMENTAL PROCEDURES
Subjects
Paired samples of Vis and SC adipose tissue were obtained from 196
Caucasian men (n = 98) and women (n = 98) who underwent open
abdominal surgery for gastric banding, cholecystectomy, appendec-
tomy, weight reduction surgery, abdominal injuries, or explorative lap-
arotomy. Subjects undergoing gastric bypass were excluded from the
study. Subjects who underwent appendectomy were included only if
there was no inflammation of the appendix. Subjects with any acute
or chronic inflammatory disease as determined by a leukocyte count
> 7000 gigaparticles/liter, C-reactive protein > 5.0 mg/dl, or clinical
signs of infection were excluded from the study. Euglycemic-hyperin-
sulinemic clamp studies were performed prior to surgery in subjects
undergoing gastric banding or other weight reduction surgery or
3 months after surgery in subjects who underwent nonelective surger-
ies. Blood sampling was performed prior to clamp studies. Subject
age ranged from 23 to 86 years, and BMI ranged from 20.8 to
54.1 kg/m2. Sixty-six subjects were lean (BMI% 25), and 130 subjects
were obese (BMIR 30). Sixty-seven subjects had either T2D (n = 36) or
IGT (n = 31). Subgroup analyses demonstrated that IGT and T2D sub-
jects were indistinguishable with regard to RBP4 serum and mRNA
measurements, and these groups were therefore studied together
(n = 67). All subjects had a stable body weight that fluctuated no
more than 2% for R3 months before surgery. Subjects with severe
conditions including generalized inflammation or advanced malignant
diseases were excluded from the study. Samples of Vis and SC adi-
pose tissue were immediately frozen in liquid nitrogen after biopsy.
The study was approved by the ethics committee of the University of
Leipzig and conformed to the Declaration of Helsinki. All subjects
signed informed consent forms before taking part in the study.
Measures of Body Fat Content and Distribution
BMI was calculated as weight/height2. Waist and hip circumferences
were measured; waist-to-hip ratios were calculated. Percentage
body fat was measured by dual X-ray absorptiometry (DEXA). Vis fat
area and the relative ratio of intra-abdominal Vis fat to SC fat area
were determined using CT scans at the level of L4–L5 with an attenu-
ation range of 30 to 190 Hounsfield units as described (Berndt
et al., 2005).
Euglycemic-Hyperinsulinemic Glucose Clamp
Insulin sensitivity was measured using the euglycemic-hyperinsuline-
mic clamp method, with an insulin infusion rate of 20 mIU/kg/min, as
described (DeFronzo et al., 1979). The glucose disposal rate was
defined as the glucose infusion rate during the last 30 min of the study.
The maximal glucose infusion rate was capped at 99 mmol/kg/min in
insulin-sensitive subjects.
Analysis of Human RBP4 Gene Expression
Human RBP4 mRNA levels were measured by quantitative real-time
PCR using an ABI PRISM 7000 sequence detector (Applied Biosys-
tems). See Supplemental Experimental Procedures for further details.
Measurements of Serum RBP4 and TTR Concentrations
Serum was obtained after an overnight fast. RBP4 and TTR were
measured by quantitative western blotting (Graham et al., 2006) with
protein standards prepared with purified full-length human recombi-
nant RBP4 and purified human plasma TTR (Sigma). Immunodetection
was performed with polyclonal antibodies to human RBP4 and TTRCell Metabolism 6, 79–87, July 2007 ª2007 Elsevier Inc. 85
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RBP4 in Visceral and Subcutaneous Adipose Tissue(Dako). Percent coefficient of variation for interassay replicate samples
was less than 10% for RBP4 and less than 8% for TTR.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, one figure, and one table and can be found
with this article online at http://www.cellmetabolism.org/cgi/content/
full/6/1/79/DC1/.
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